X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
QN-302 is a small molecule G-Quadruplex (G4)-selective transcription inhibitor in Phase 1 clinical development for the treatment of G4-expressing solid tumors, such as pancreatic cancer (PDAC), prostate cancer, sarcomas, and others.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
QN-302 (formerly SOP1812) is a G4 selective transcription inhibitor. QN-302 is a small molecule drug candidate with superior efficacy and activity against pancreatic cancer.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
F3-8-60, pan-RAS inhibitor with efficacy in malignant peripheral nerve sheath tumors and pancreatic cancer,demonstrated the ability to inhibit the metastasis of a malignant peripheral nerve sheath tumor cell line.
Lead Product(s): F3-8-60
Therapeutic Area: Oncology Product Name: F3-8-60
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
QN-247 demonstrated a robust efficacy signal and showed no adverse events or toxicities at the tested therapeutic dose in an animal model for triple negative breast cancer (TNBC), a rare, highly aggressive and difficult to treat form of breast cancer.
Lead Product(s): QN-247
Therapeutic Area: Oncology Product Name: QN-247
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for Pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need, such as Prostate Cancer.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hande Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 06, 2022
Details:
QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for PDAC, in addition to other tumors of high unmet clinical need.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Qualigen’s RAS-F, is a family of small molecules designed to prevent mutated RAS gene proteins from binding to their effector proteins. Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to impact tumor growth in multiple in vivo models.
Lead Product(s): RAS-F
Therapeutic Area: Oncology Product Name: RAS-F
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
